CLINICAL TRIALS PROFILE FOR PARICALCITOL
✉ Email this page to a colleague
All Clinical Trials for paricalcitol
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00048438 ↗ | Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly) | Completed | Abbott | Phase 3 | 2002-02-01 | The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease. |
| NCT00048451 ↗ | Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly) | Completed | Abbott | Phase 3 | 2002-02-01 | The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease. |
| NCT00048516 ↗ | Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing) | Completed | Abbott | Phase 3 | 2002-02-01 | The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease. |
| NCT00064376 ↗ | Paricalcitol in Treating Patients With Myelodysplastic Syndrome | Completed | Abbott | Phase 2 | 2003-05-01 | RATIONALE: Paricalcitol is a form of vitamin D that may help myelodysplastic cells develop into normal bone marrow cells. PURPOSE: Phase II trial to study the effectiveness of paricalcitol in treating patients who have myelodysplastic syndrome. |
| NCT00064376 ↗ | Paricalcitol in Treating Patients With Myelodysplastic Syndrome | Completed | Cedars-Sinai Medical Center | Phase 2 | 2003-05-01 | RATIONALE: Paricalcitol is a form of vitamin D that may help myelodysplastic cells develop into normal bone marrow cells. PURPOSE: Phase II trial to study the effectiveness of paricalcitol in treating patients who have myelodysplastic syndrome. |
| NCT00217477 ↗ | Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer | Completed | Abbott | Phase 1 | 2004-08-01 | RATIONALE: Paricalcitol may cause cancer cells to look more like normal cells, and to grow and spread more slowly. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving paricalcitol together with gemcitabine may be an effective treatment for cancer. PURPOSE: This phase I trial is studying the side effects and best dose of paricalcitol when given together with gemcitabine in treating patients with advanced cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for paricalcitol
Condition Name
Clinical Trial Locations for paricalcitol
Trials by Country
Clinical Trial Progress for paricalcitol
Clinical Trial Phase
Clinical Trial Sponsors for paricalcitol
Sponsor Name
